

26th February, 2024

To,
The Manager - Corporate Relationship
Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

To,
The Manager - Corporate Compliance
National Stock Exchange of India Limited
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051

BSE Scrip Code: - 524500

NSE SYMBOL: - KILITCH

Sub: Press Release

Dear Sir,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release relating to tender won by Kilitch Estro Biotech PLC, subsidiary of Kilitch Drugs (India) Limited.

Request you to take note of the same and acknowledge the receipt.

Thanking you,

Yours' Faithfully,

For **Kilitch Drugs (India) Limited**

Mukund Mehta
Managing Director
DIN: 00147876





Kilitch Drug (India) Limited's Subsidiary Won Tender Issued by the Ethiopian Pharmaceutical Supply Service of the Federal Democratic Republic of Ethiopia

Mumbai February 26, 2024, Kilitch Drug (India) Limited, (BSE CODE:524500, NSE CODE: KILITCH), a multi-national pharmaceutical company based in Mumbai, has announced that its subsidiary, Kilitch Estro Biotech PLC, has secured a significant tender issued by the Ethiopian Pharmaceutical Supply Service of the Federal Democratic Republic of Ethiopia having value of approx. USD 9.13 million. This tender win marks a notable achievement for the company not only because of this tender but also it will definitely repeat as the Ethiopian Pharmaceutical Supply Service has planned to purchase injectable from local manufacturer.

The contract awarded to Kilitch Estro Biotech PLC entails the supply of pharmaceuticals with an order size amounting to USD 9.13 million. The contract is executable within a timeline of six months from the receipt of the order, highlighting the efficiency and capability of Kilitch Drug (India) Limited's subsidiary in fulfilling such large-scale contracts.

This accomplishment further solidifies Kilitch Drug's position in the pharmaceutical industry, showcasing its ability to secure substantial contracts and expand its presence in international markets.

Commenting on the receipt of the order **Mr. Mukund Mehta, Managing Director of Kilitch Drug (India) Limited** said, "It is a significant achievement for the company. Securing an order from a government entity in Ethiopia represents a milestone moment, opening doors for Kilitch Drug to engage in government contracts, which speaks volumes about the quality and reliability of our products and supply chain. We anticipate recurring orders from The Federal Democratic Republic of Ethiopia.

Receipt of this order strengthens Kilitch Drug's presence in Ethiopia and positioning the company to capture a larger share of the Ethiopian market."

About Kilitch Drug (India) Limited

Kilitch Drug (India) Limited Group is a prominent pharmaceutical solution provider established in 1992. With its roots deeply embedded in Africa, the company has expanded its reach across key African countries among others. Situated in Mumbai with its manufacturing sites at Mumbai, Ethiopia and upcoming sites at Khopoli Maharashtra having facilities for dry powder, ophthalmic products, nasal products as well as the capacity to produce small volume liquid ampoules and vials. The plant's adherence to quality standards is underscored by its certification from the World Health Organization (WHO).

The company prides itself on its extensive product portfolio, spanning various therapeutic areas such as gastroenterology, anti-inflammatory, anti-malarial, Ophthalmic, uterine stimulants, veterinary medicines, and more.

Kilitch Drug's strong clientele is a testament to its reputation and reliability in the industry as it acknowledges the robust consolidated financial performance par excellence indicating its sustainability and profitability in the global market.

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information you may reach to:



Kilitch Drugs (India) Limited

Pushpa Nyoupane - Company Secretary

pushpanyoupane@kilitch.com

022 61214122

www.kilitch.com